Efavirenz/Emtricitabine/Tenofovir Alafenamide Fumarate

依非韦伦/恩曲他滨/富马酸磷丙替诺福韦

Report date: 2025/07/29 17:48:13

Base Information

Drug NameEfavirenz/Emtricitabine/Tenofovir Alafenamide Fumarate
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/03/22
Country/TerritoryUnited States
CombinationsYes EfavirenzEmtricitabineTenofovir Alafenamide Fumarate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMylan Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMylan Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A